Table 1.
0 | 1 | 2 | 3 | 4 | Control group | Study group | p- value | |
---|---|---|---|---|---|---|---|---|
Mucosal loss | Absent | ≤50% | >50% | 2 (2-2) | 1 (0-2) | .053 | ||
Bleeding | Absent | ≤50% | >50% | 2 (1-2) | 1 (0.5-1.5) | .166 | ||
Thrombi | Absent | Present | 1 (0.5-1) | 1 (0.5-1) | 1 | |||
Vascular lesion | Absent | ≤50% | >50% | 2 (1-2) | 1 (0.5-1) | .074 | ||
Arteriol- onecrosis | Absent | ≤50% | >50% | 2 (1.5-2) | 1 (0.5-1) | .015 | ||
Superficial duct necrosis | Absent | ≤25% | 25-50% | 50-75% | >75% | 4 (4-4) | 1 (0.5-3) | .005 |
Trans-mural duct necrosis | Absent | ≤25% | 25-50% | 50-75% | >75% | 4 (1.5-4) | 0 (0-0.5) | .032 |
Inflammation -leukocytes per high power field 0.159mm2 | Absent | At least 10 | At least 50 | 0 (0-0.5) | 0 (0-0.5) | 1 | ||
Inflammation -lymphocytes per high power field 0.159mm2 | Absent | At least 10 | At least 50 | 1 (0.5-1.5) | 1 (0-1.5) | .650 | ||
Loss of periluminal peribiliary glands (PBGs) | Absent | ≤50% | >50% | 1 (1-2) | 0 (0-1) | 0 (0-1) | ||
Loss of deep PBGs | Absent | ≤50% | >50% | 1.5 (0.25-2) | 0 (0-0) | .046 | ||
Total | 19 (14.5-22) | 6 (3-13) | 0.028 |